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Introduction
Despite intense efforts at epidemiological tracking and computa-
tional modeling, the timing and severity of influenza outbreaks 
remain difficult to predict, as illustrated by the last two influenza 
seasons. On average, influenza-like illness (ILI) reports exceed 
the Centers for Disease Control and Prevention’s (CDC) national 
baseline for a period of 12 weeks. During the 2011–2012 sea-
son, there was only one week of ILI reports above baseline. In 
contrast, the 2012–2013 season saw the earliest outbreak since 
2003–2004, and roughly 15 weeks of ILI reports above baseline 
were documented.1
Vaccination is the only public-health means for reducing the 
impact of influenza morbidity and mortality by offsetting the 
uncertainties of timing and virulence arising from uncontrollable 
complexities of population, behavioral, viral, and environmen-
tal factors. Vaccination is also considered a cornerstone approach 
for pandemic preparedness. The principle approach to influ-
enza vaccine design focuses on raising antibodies that prevent 
Immune responses to cross-conserved T cell epitopes in novel H1N1 influenza may explain reports of diminished influenza-
like illnesses and confirmed infection among older adults, in the absence of cross-reactive humoral immunity, during the 
2009 pandemic. These cross-conserved epitopes may prove useful for the development of a universal H1N1 influenza 
vaccine, therefore, we set out to identify and characterize cross-conserved H1N1 T cell epitopes. an immunoinformatic 
analysis was conducted using all available pandemic and pre-pandemic Ha-H1 and Na-N1 sequences dating back to 
1980. using an approach that balances potential for immunogenicity with conservation, we derived 13 Ha and four Na 
immunogenic consensus sequences (IcS) from a comprehensive analysis of 5,738 Ha-H1 and 5,396 Na-N1 sequences. 
These epitopes were selected because their combined epitope content is representative of greater than 84% of pre-
pandemic and pandemic H1N1 influenza strains, their predicted immunogenicity (epiMatrix) scores were greater than or 
equal to the 95th percentile of all comparable epitopes, and they were also predicted to be presented by more than four 
HLa class II archetypal alleles. We confirmed the ability of these peptides to bind in HLa binding assays and to stimulate 
interferon-γ production in human peripheral blood mononuclear cell cultures. These studies support the selection of the 
IcS as components of potential group-common H1N1 vaccine candidates and the application of this universal influenza 
vaccine development approach to other influenza subtypes.
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hemagglutination. Generally, vaccination does induce hemagglu-
tinating antibodies but these antibodies are neither cross-reac-
tive with other strains, nor persistent. Furthermore, vaccination 
against influenza is only moderately effective. A meta-analysis 
using data from randomized, controlled trials conducted over 12 
seasons and published between 1967 and 2011 demonstrated that 
trivalent influenza vaccination (TIV) in adults aged 18–65 years 
provided only moderate protection (59%) over eight seasons and 
significantly lower levels in other seasons.2 Live attenuated influ-
enza vaccine (LAIV), which stimulates both cellular and humoral 
immunity, showed higher efficacy (83%) in children aged 6 to 17 
years, but not in adults. To improve on the shortcomings of exist-
ing influenza vaccination approaches, novel vaccine approaches 
that aim to provide universal protection are needed.
We became interested in the concept of cross-reactive T cell 
epitopes for influenza during the 2009 H1N1 pandemic. At that 
time, the Centers for Disease Control and Prevention reported 
that seasonal flu vaccines did not elicit cross-reactive neutralizing 
antibodies against the emerging pandemic (H1N1) 2009.3 When 
D
ow
nl
oa
de
d 
by
 [7
2.2
15
.23
6.2
54
] a
t 1
2:0
7 0
8 O
cto
be
r 2
01
5 
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com Human Vaccines & Immunotherapeutics 1599
 SpecIaL FocuS ReSeaRcH papeR SpecIaL FocuS ReSeaRcH papeR
early clinical reports released during the 2009 A(H1N1) pan-
demic suggested the novel influenza was more virulent among 
children and adults under 65 years than the elderly, we hypoth-
esized that cellular responses to cross-reactive T cell epitopes 
might explain the unexpected disease distribution. The apparent 
lack of B cell epitope conservation in novel H1N1 and absence 
of cross-reactive antibodies raised by the seasonal vaccine H1N1 
strain at the time supported this idea.
Thus, we set out to identify cross-conserved T cell epitopes in 
the pandemic and the 2008–2009 seasonal vaccine hemaggluti-
nin (HA) and neuraminidase (NA) antigens, as soon as the first 
pandemic influenza sequences became available, using immuno-
informatic methods.4 The HLA class II epitope predictions were 
later confirmed experimentally using peripheral blood mono-
nuclear cells from human donors not exposed to the pandemic 
virus,5 illustrating that pre-existing CD4+ T cells elicit cross-
reactive effector responses against the pandemic H1N1 virus. In 
addition, they demonstrated that the computational tools were 
90% accurate in predicting CD4+ T cell epitopes and their HLA-
DR-dependent response profiles in donors that were chosen at 
random for HLA haplotype. As HA and NA antigens are the 
principle components of seasonal trivalent inactivated and sub-
unit influenza vaccines and CD4+ T cells support both humoral 
and cellular influenza immunity, we have now performed a sig-
nificantly expanded immunoinformatic analysis of the H1-HA 
and N1-NA sequence space to identify HLA class II-restricted 
immunogenic consensus sequences covering isolates dating back 
to 1980 from the end of the 2009 pandemic. The novel antigens 
were validated in HLA binding and T cell assays in preparation 
for future vaccine efficacy studies in HLA transgenic mice. We 
provide a detailed report on the methods used to define these 
highly cross-conserved influenza vaccine epitopes. The method 
may be of interest for the design of future H7N9, H5N1, and 
H3N2 vaccines.
Results
9-mer conservation and HLA binding potential. Influenza 
H1N1 HA and NA sequences dating back to 1980 were compu-
tationally screened in a step-wise process to identify conserved 
and potentially immunogenic epitopes (Fig. 1). A total of 5,738 
influenza A H1-HA sequences were collected, comprising 4,110 
(71.6%) pandemic 2009 and 1,628 (28.3%) pre-pandemic 
sequences. A total of 3,200,273 9-mers were parsed from these 
sequences and duplicates were removed, leaving 16,247 unique 
9-mers (0.5%). Of the unique HA 9-mers, 3,396 were predicted 
by EpiMatrix to bind to at least one of eight archetypal HLA 
class II alleles (20.1%). One hundred and sixty-eight 9-mers were 
found in more than 75% of the input HA proteins (Fig. 2A), 
covering an average of 99% and 95% of pandemic and pre-pan-
demic sequences, respectively. A set of 5,396 influenza A N1-NA 
sequences was also assembled, including 3,574 (66.2%) pan-
demic and 1,822 (33.8%) pre-pandemic, post-1980 sequences. 
From these N1-NA sequences, 2,488,564 9-mers were parsed, 
11,065 of which were classified as unique (0.4%). Of the unique 
NA 9-mers, 2,147 (19.4%) were predicted to bind to at least one 
Figure 1. Informatic-driven identification of influenza H1N1 hemagglu-
tinin and neuraminidase immunogenic consensus sequences. Results 
of the step-wise computational process of screening H1-Ha and N1-Na 
sequences for conserved and potentially immunogenic epitopes and 
constructing immunogenic consensus sequences are shown.
Figure 2. conservation distribution of influenza H1N1 hemagglutinin 
and neuraminidase 9-mers. pre-pandemic and pandemic H1-Ha (A) 
and N1-Na (B) sequences were parsed into overlapping nine amino 
acid frames with a one amino acid frameshift, and unique 9-mers were 
evaluated for percent coverage of source antigens at 100% sequence 
identity using the conservatrix algorithm. Inset: close-up of the 
75–100% coverage range.
D
ow
nl
oa
de
d 
by
 [7
2.2
15
.23
6.2
54
] a
t 1
2:0
7 0
8 O
cto
be
r 2
01
5 
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
1600 Human Vaccines & Immunotherapeutics Volume 9 Issue 7
receptor-facing pattern with predicted mouse MHC-binding 
sequences, despite H1-1 and N1-1 containing 9-mers with seven 
out of nine identities. Potential cross-reactivity between H1-7, 
H1-9, N1-1, and N1-4 ICS and human commensal sequences was 
also considered to be negligible, using JanusMatrix. In contrast, 
a screen of non-influenza pathogens uncovered multiple 9-mers 
with 7 out of 9 identities, although few were well matched by 
HLA allele and TCR-facing side chains. The “other pathogen” 
that matched most often to ICS peptides was Salmonella Typhi, 
with similar sequences observed in H1-2, -3, -4, -5, -8, and -13. 
Notably, in a screen of H5N1 influenza HA and NA sequences, 
five HA and four NA ICS were found to be homologous. This 
suggests that this methodology has identified influenza sequences 
that are both highly conserved and potentially immunogenic, 
enhancing their utility as universal influenza vaccine candidate 
epitopes.
HLA binding. ICS peptides were assayed in vitro for their 
capacity to bind multiple HLA types, including DRB1*0101, 
DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, and 
DRB1*1501. Of the 108 ICS peptide-HLA binding interactions 
assayed, 3% bound with very high affinity, 23% bound with 
high affinity, 26% bound with moderate affinity, 30% bound 
with low affinity, 2% with very low affinity, and 15% had no 
affinity for the HLA tested (Fig. 4).
All (100%) of the peptides bound as predicted to at least three 
HLA alleles, 89% to at least four HLA alleles, 72% to at least five, 
and 39% to all six. A non-binder was defined as a confirmed pre-
diction (true negative) if the peptide had an EpiMatrix Z-score 
that was lower than the defined cut-off (1.64) for its associated 
HLA allele. Positive predictions were defined as epitopes scoring 
≥ 1.64 on the EpiMatrix Z-scale and binding HLA at any affinity. 
The concordance of computational predictions and binding assay 
results was evaluated with classification of peptide-HLA binding 
pairs as either true positive, false positive, true negative, or false 
negative. Overall, the concordance with predictions (both posi-
tive and negative) was 83%. With respect to each allele assayed, 
HLA class II allele. One hundred and twenty-two 9-mers were 
found in more than 75% of the input NA proteins (Fig. 2B), 
covering 99% of pandemic and 96% of pre-pandemic sequences.
Interestingly, a second cluster of “high-range” conserved 
9-mers was observed in the conservation distribution of both pro-
tein sets (Fig. 2). Three hundred 87 HA 9-mers (2.3%) and 339 
NA 9-mers (3.1%) were found in 50–74% of input sequences. 
These sequences may represent regions that tolerate limited vari-
ability on the level observed in antigenic shifts. The remaining 
15,692 HA (96.5%) and 10,604 NA peptides (95.8%) were 
found in < 50% of input sequences with 14,671 HA and 9,744 
NA peptides conserved in < 1% of unique 9-mers, as is expected 
for these highly variable antigens.
ICS construction and selection. Drawing from the set of 
9-mer sequences with >75% conservation, a total of 19 immuno-
genic consensus sequences (ICS) derived from HA and eight ICS 
from NA were constructed by the EpiAssembler algorithm. This 
algorithm has been used to identify consensus sequences from 
highly variable proteins that are balanced for immunogenicity 
and conservation.6,7 One drawback to the approach is that given 
the large sampling of protein isolates, identifying multiple simi-
lar, though not identical, 9-mers that derive from the same region 
of HA or NA and retain significant HLA binding potential is 
highly likely. Indeed, 6 ICS from the HA set were eliminated due 
to redundant core peptide sequences. In this case, we selected the 
sequence that had the highest conservation from the set of redun-
dant sequences. A final set of 13 HA and four NA ICS epitopes 
was retained based on the previously defined characteristics: high 
influenza strain coverage (>85% conservation among input pro-
teins), excellent immunogenicity scores (EpiMatrix cluster scores 
> 10), and promiscuous HLA binding potential (Fig. 3; Table 1). 
All HA and NA ICS are homologous to published HLA ligands 
and/or HLA DR-restricted T cell epitopes, according to a BLAST 
screen of the Immune Epitope Database at 90% coverage.8
By sequence comparison, we evaluated the potential for the 
selected H1N1 ICS to trigger immune responses from pre-exist-
ing T cells that bear TCR specific for epitopes contained in host 
or commensal antigens. We normally eliminate any such cross-
reactive epitopes because activation of T cells cross-reactive with 
self or with commensals in the context of immunization may lead 
to unexpected immune responses that limit efficacy. For example, 
activation of cross-reactive host-specific natural regulatory T cell 
activation may dampen vaccine responses. Alternatively, T cells 
that express T cell receptors (TCRs) trained on commensal anti-
gens may lead to induction of cross-reactive T cells with effector 
phenotypes, an event that may perturb immune homeostasis. By 
BLAST analysis, no homology between influenza and human 
sequences was identified in any of the final 17 ICS selections. 
Even though 12 ICS were observed to be homologous to murine, 
commensal, and other pathogen (non-influenza) sequences, they 
were not eliminated from the final set selected for experimental 
validation. None of these ICS bear TCR-facing sequences that 
are fully conserved with their murine and commensal homologs 
and preserve MHC binding potential, suggesting a low prob-
ability for cross-reactivity. Using a new tool that evaluates TCR 
facing residues, JanusMatrix,9 we found no ICS shares a T cell 
Figure 3. Immunogenic consensus sequence influenza H1N1 strain 
coverage and HLa binding potential. IcS construction yielded 13 H1-Ha 
and four N1-Na sequences with >85% coverage of input proteins and 
epiMatrix cluster scores >10, representing significant HLa binding po-
tential. Bars represent epiMatrix cluster score and open circles percent 
strain coverage.
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both overall and for individual alleles. Additionally, prediction/
experimental discrepancies are introduced in binding assays by 
epitope-specific factors, including peptide design and the unique 
physical and chemical properties of individual peptides that, for 
example, may contribute to aggregation.
T cell reactivity. To further support the choice of these immu-
nogenic consensus sequences as potential vaccine candidates, we 
stimulated human peripheral blood mononuclear cells (PBMCs) 
with ICS peptides and measured cytokine production to demon-
strate that the peptides are immunoreactive. While HLA bind-
ing assays establish that a sequence can be presented to T cells, 
cytokine measurements demonstrate epitope antigenicity. Over a 
the values are 88% for DRB1*0101, 76% for DRB1*0301, 88% 
for DRB1*0401, 78% for DRB1*0701, 82% for DRB1*1101, and 
82% for DRB1*1501. These HLA-binding and epitope predic-
tion results are consistent with previously published studies using 
the same algorithms and assay conditions.10,11
Discrepancies between computational predictions and 
experimental results are expected, in part, because immunoin-
formatic algorithms are not 100% accurate. A recent retrospec-
tive evaluation of epitope mapping algorithm accuracy showed 
EpiMatrix was > 75% accurate across all the HLA class II alleles 
studied here.12 In comparison with other major prediction tools, 
EpiMatrix compared favorably, with equal or greater accuracy 
Table 1. H1N1 immunogenic consensus sequences
A
Hemagglutinin Immunogenic Consensus Sequences % Coverage IEDB
#
HA 
POS
N 
TERM
CORE PEPTIDE
C 
TERM
# Hits
CLUSTER 
SCORE
# 
EpiBars
All H1N1
Pandemic 
H1N1
Pre-
Pandemic 
H1N1 HLA 
Binding
T Cell 
Assay2273 
unique 
Sequences
1410 unique 
Sequences
870 
unique 
Sequences
1 112 FIQ YeeLReQLSSVS aFe 9 14.78 1 98.7% 98.7% 97.0% Y
2 440 aeM LVLLeNeRTLDY YDS 10 16.02 1 99.2% 98.9% 99.2% Y Y
3 523 eSa RIYQILaIYSTVaS TLV 15 25.59 3 99.6% 99.0% 99.2% Y
4 396 VNS IIeKMNTQFTaVG KeF 8 11.07 1 98.9% 98.4% 99.2% Y Y
5 527 IYQ ILVIYSTVaSSLVL SVS 20 35.15 4 98.6% 98.1% 99.2% Y
6 463 YeK VRSQLKNNaKeIG NGc 12 22.54 2 99.0% 96.3% 98.5% Y
7 548 GaV SFWMcSNGSLQ FRI 7 11.78 1 97.4% 95.8% 99.7% Y
8 432 FMD IWTYNaeLLVLL DNe 7 10.15 1 99.7% 99.3% 100.0% Y Y
9 38 eRN VTVTHSVNLLe eKH 8 13.13 1 95.1% 92.4% 99.0% Y
10 19 TLS IGYHaNNSTDT eDT 6 10.35 1 99.7% 99.6% 99.5% Y
11 326 STR LRMVTGLRNVpSIQS KGL 17 28.36 3 93.3% 92.0% 93.3% Y Y
13 386 QNa INRITNKVNSVI KKM 8 11.54 2 96.8% 98.2% 94.5% Y
19 337 NVp FIQSRGLFGaIaGFI eGG 12 19.73 2 99.5% 99.2% 99.1% Y Y
B
Neuraminidase Immunogenic Consensus Sequences % Coverage IEDB
#
NA 
POS
N 
TERM
CORE PEPTIDE
C 
TERM
# Hits
CLUSTER 
SCORE
# 
EpiBars
All H1N1
Pandemic 
H1N1
Pre-
Pandemic 
H1N1
HLA 
Binding
T Cell 
Assay
2273 
unique 
Sequences
1410 unique 
Sequences
870 
unique 
Sequences
1 129 cRN FFLTQGaLLN DRH 12 23.64 2 98.4% 99.1% 97.8% Y
2 79 SVL SVKLaGNSSLcS TSG 12 22.78 2 89.2% 92.1% 82.8% Y Y
3 17 IIG LILQIGNIISI WpV 14 27.31 2 93.2% 96.6% 89.7% Y
4 439 SGS IISFcGVNSDTV DWS 7 11.19 1 80.6% 95.4% 65.5% Y
Key features of Ha and Na IcS produced by the epiassembler algorithm are presented, including position in the native antigen sequence relative to 
Influenza a/california/04/2009 (Ha/Na poS), N- and c-terminal flanking residues (NTeRM/cTeRM), core immunogenic peptide sequence (coRe pepTIDe), 
epiMatrix 9-mer-to-HLa-allele hits (#HITS), overall peptide promiscuous binding potential where ≥ 10 is significant (cLuSTeR ScoRe), number of 9-mers 
with promiscuous binding potential where ≥ 1 is significant (#epiBars). peptides previously shown to bind HLa-DR (IeDB: HLa Binding) or to stimulate 
HLa-DR-restricted T cell responses (IeDB: T cell assays) as reported in the Immune epitope Database are noted. conservation is summarized by classifica-
tion (pandemic vs. pre-pandemic) and overall. % coverage describes how many of the individual protein isolates are represented with at least one of the 
HLa-binding 9-mers in an IcS.
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morbidity and mortality.14 One explanation for this unexpected 
observation is that pre-existing influenza-specific CD4+ T cells 
generated cross-reactive responses against the virus that were 
capable of limiting disease severity and virus spread in individu-
als lacking cross-protective humoral immunity. This hypothesis 
is supported by a number of in vitro and in vivo studies: inde-
pendent studies demonstrated cytotoxic T lymphocytes (CTLs) 
and CD4+ T cells raised against the seasonal H1N1 viruses, A/
Brisbane/59/2007 and A/New Caledonia/20/99, respectively, 
were capable of responding against whole protein antigens from 
the pH1N1 virus.5,15-17 In mice and in humans, memory T cells 
to conserved epitopes have been shown to confer protection to 
heterotypic infection.18,19 In addition, cross-reactive human T 
helper cell responses were observed for HLA-DR4 epitopes.20 
Moreover, ferrets infected with seasonal H1N1 influenza, though 
lacking sterilizing immunity, were protected from disease upon 
subsequent pH1N1 infection.21 During the pandemic, a lower 
hospitalization rate and lower reports of H1N1 infection among 
recent seasonal vaccinees was observed in a case-control study 
in Mexico.22 And finally, a T cell-driven influenza vaccine was 
recently shown to be protective against influenza challenge in 
human studies.23 Taken together, these studies support the use-
fulness of including influenza antigens that can elicit cross-strain 
T helper cell responses in a universal influenza vaccine.
The activation of helper T cells is also critically important to 
the magnitude, quality, and kinetics of antibody response.24 In 
the absence of functional (memory) CD4+ T cells, mouse stud-
ies have shown that the rate of viral clearance upon secondary 
nine-day period, we expanded antigen-specific T cells from five 
young adult subjects, with unknown influenza infection and vac-
cination history, by stimulation with a pool of HA and NA ICS 
peptides. Cells were then re-stimulated with pooled or individual 
ICS peptides for measurement of interferon-γ (IFNγ) produc-
tion by ELISpot assay. Cultured ELISpot assays were performed 
because ex vivo responses were not robust, suggesting that anti-
gen-specific T cell precursor frequencies were too low to observe 
without amplification (data not shown). Cultured ELISpot 
responses were significantly greater than ex vivo responses and 
were considered positive when (1) the number of IFNγ spot-
forming cells exceeded 50 per million PBMCs cultured, (2) 
spot counts were at least twice background, and (3) spot counts 
were statistically different from “no stimulus” measurements 
(p < 0.05). All subjects responded to the pool of ICS peptides 
(Fig. 5; Table 2). Apart from Subject 844, all pooled peptide 
re-stimulations elicited robust numbers of IFNγ-producing cells, 
ranging from 1127 to 4737 per million PBMCs with stimulation 
index values at least three times the cutoff value of two. It is pos-
sible Subject 844 did not respond strongly to the ICS peptides 
because of no prior history of H1N1 exposure or vaccination. 
These data show that H1N1 cross-reactive memory T cell precur-
sors do exist and have the potential to be substantially expanded 
by vaccination with universal H1N1 antigens.
Individual ICS peptides stimulated significant IFNγ produc-
tion in all subjects but Subject 844 (Table 2). Excluding this 
subject, positive responses per subject ranged from 24% to 65% 
over all 17 ICS peptides. By source antigen, positive responses 
ranging from 31% to 69% per subject were observed for the 13 
HA ICS peptides and 0% to 50% for the four NA ICS peptides. 
Thirteen out of the 17 ICS peptides (76%) stimulated positive 
responses in at least one subject. By source antigen, 10 out of 13 
HA ICS (77%) and 3 out of 4 NA ICS (75%) peptides were posi-
tives. Two ICS peptides, HA-3 and HA-8, were immunoreactive 
in all cases except Subject 844, suggesting that T cells specific for 
these sequences may be immunodominant. Unexpectedly, four 
ICS peptides stimulated no responses in any subjects. The small 
cohort size of the study with limited HLA diversity may explain 
this result. Alternatively, these sequences may stimulate type 1 
helper T cell cytokines other than IFNγ, such as interleukin-2 
and tumor necrosis α. Additionally, vaccination may increase the 
numbers of precursor cells to the level needed for detection by 
cultured ELISpot. Thus, positive responses may be observed in 
a larger cohort with broader HLA coverage, comparing multiple 
cytokine responses in samples drawn before and after vaccina-
tion. Future studies will address these factors.
Discussion
Cross-reactive T cell epitopes such as the ones identified here may 
have played a significant role in containing the human impact 
of the 2009 influenza H1N1 pandemic. Despite studies show-
ing pandemic H1N1 was highly pathogenic in laboratory ani-
mals and shared few B cell epitopes with most seasonal H1N1 
viruses,13 the virus triggered only mild symptoms in middle-aged 
and elderly adults and, fortunately, failed to cause widespread 
Figure 4. IcS peptide – HLa DR binding affinities. peptide identifiers 
and sequences are noted in the first and second columns, respectively. 
Ic50 values in μM units were calculated from curves fitted to dose-
dependence competition binding data for each peptide-HLa DR allele 
pair. peptide binding affinity is shown according to the following clas-
sification: Ic50 < 0.1 μM (black), 0.1 μM < Ic50 < 1 μM (dark gray),  
1 μM < Ic50 < 10 μM (gray), 10 μM < Ic50 < 100 μM (light gray), Ic50 > 
100 μM (lightest gray). Ic50 values too high to accurately measure under 
binding conditions tested are considered non-binders (NB; shown in 
white cells).
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The comprehensive approach to defining highly conserved 
H1N1 sequences described here builds on our initial analysis and 
identification of cross-conserved H1-HA and N1-NA T-cell epi-
topes that was published during the 2009 influenza A(H1N1) 
pandemic. A comparison of the results from these two indepen-
dent analyses shows that the wider net cast for H1N1 sequences 
in the present study yielded a set of sequences, some of which 
are similar and some different from the original screen. Nine of 
13 ICS derived from this collection of HA antigens and three 
of four NA ICS newly derived in the present work are similar to 
those identified in the initial analysis. Additionally, we previously 
identified three cross-conserved immunogenic sequences from 
each antigen, which were not sufficiently conserved in the larger 
sequence data set to be represented in the final selections made 
here. This comprehensive set of more highly conserved H1N1 
sequences will be further tested in in vivo studies with HLA 
transgenic mice, before moving them forward into formulation 
studies for vaccine development purposes.
We used HLA binding as a proxy for immunogenicity, 
although binding is not an absolute indicator of immunoge-
nicity potential. The results showed that the ICS peptides are 
promiscuous binders, suggesting they may be broadly immuno-
reactive. As well, they showed that the immunoinformatic pre-
dictions were highly (83%) accurate. Furthermore, in vitro T cell 
responses to 76% of the individual ICS peptides were observed 
in a small cohort of healthy subjects. In addition, the results con-
firmed epitopes that have been previously published, based on 
a search of the IEDB. While our report focuses on HLA class 
II-restricted CD4+ T helper epitopes, CTLs are also required for 
viral clearance, some of which may be CD4+.32 Taken together, 
the combination of epitope prediction and HLA binding and 
immunoreactivity data here shows that these cross-conserved 
influenza sequences have promiscuous HLA binding and anti-
genicity properties required to identify broadly reactive, cross-
protective H1N1 influenza-specific T cells raised in infection or 
vaccination and to serve as immunogens in a universal H1N1 
influenza vaccine.
The level of conservation of these sequences among H1N1 
sequences extending from 1980 to 2011 is quite remarkable and 
illustrates the capacity of epitope-mapping tools to discover high-
value sequences for vaccine design. The immunoinformatics 
approach described here allows for the identification and charac-
terization of cross-conserved T cell epitopes for any set of source 
sequences. Notably, this universal influenza vaccine development 
approach may be applied to other influenza subtypes (H7, H5, 
for example). We have also developed tools that identify highly 
cross-conserved CD8+ T cell responses and have validated their 
accuracy.33-35 Highly efficient algorithms, such as these, may be 
useful for accelerated development of vaccines against emerging 
infections in the context of newly emerging infections or bioter-
ror events.36
An important safety feature of the vaccine design approach 
described here is that T cell epitopes that have a high degree of 
cross-conservation with human genome are taken into consid-
eration and eliminated from the list of epitopes to be tested and 
included in vaccine constructs, as there is at least initial evidence 
infection slows considerably, beyond the degree seen in the pri-
mary response.25-27 Also in mice, cross-reactive memory T helper 
cells have been shown to contribute to cross-strain antibody 
responses.28 In human populations, cross-reactive T cell responses 
have been observed between circulating strains of influenza and 
epidemic strains (such as H5N1) in the absence of cross-reactive 
antibodies.29 Both cross-reactive CTLs and T helper cells have 
been identified by a number of investigators.30,31 T cell responses 
to conserved epitopes may be particularly important when new 
strains of influenza emerge.
Figure 5. antigen-specific human IFNγ eLISpot responses to compu-
tationally identified influenza Ha and Na immunogenic consensus 
sequences. IcS were assayed for T cell reactivity by IFNγ eLISpot assay 
using pBMcs isolated from normal human donors (n = 5). an eLISpot 
response was considered positive if three criteria were met: (1) spot-
forming cells (SFc) per million pBMc were at least 50 over background; 
(2) SFc per million pBMc were at least 2-fold over background; and (3) 
antigen-stimulated SFc numbers were statistically different (p < 0.05) 
from non-stimulated counts. (A) The numbers of SFc over background 
per million pBMcs that secrete IFNγ in response to individual and 
pooled influenza Ha and Na IcS are presented. Individual subject 
responses are represented by dots and the average response across 
subjects by horizontal lines. The 50 SFc over background per million 
pBMcs cutoff is denoted by the dotted line. (B) The eLISpot response 
stimulation index, representing the ratio of antigen-stimulated SFc 
counts to non-stimulated counts, is presented. Stimulation index values 
per individual subject are represented by dots and the average values 
across subjects by horizontal lines.
D
ow
nl
oa
de
d 
by
 [7
2.2
15
.23
6.2
54
] a
t 1
2:0
7 0
8 O
cto
be
r 2
01
5 
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
1604 Human Vaccines & Immunotherapeutics Volume 9 Issue 7
“Pandemic,” whereas all other isolates were designated “non-
Pandemic H1N1,” according to the SOP for New Pandemic 
(H1N1) Classification (http://www.fludb.org/brcDocs/
documents/2009H1N1vSOP.pdf).
Conservation analysis. Because the HLA binding groove 
accepts 9-mer peptides, input HA and NA sequences were parsed 
into overlapping 9-mer frames, irrespective of protein alignment, 
using the Conservatrix algorithm. All resulting 9-mers were 
ranked by their conservation within each antigen set.
EpiMatrix analysis. All unique 9-mers resulting from 
Conservatrix analysis were scored for binding potential against 
a panel of eight representative class II HLA alleles using the 
EpiMatrix algorithm.40 The peptide-binding preferences of these 
alleles, HLA DRB1*0101, *0301, *0401, *0701, *0801, *1101, 
*1301 and *1501, are expected to cover over 95% of human pop-
ulations worldwide.41 EpiMatrix scores for each allele are normal-
ized on a Z-scale; peptides scoring > 1.64 are called “hits.” These 
sequences represent the top 5% of any normally distributed set 
of 9-mer peptides and are highly likely to be true HLA ligands.
Construction of immunogenic consensus sequences. The 
EpiAssembler algorithm was employed to create immuno-
genic consensus sequences (ICS) using data collected during 
that such epitopes may be immunopathogenic (refs. 9, 37, 38 and 
Losikoff P et al., in preparation), or tolerated by the immune sys-
tem, or they may stimulate regulatory T cell responses.9
Accumulating evidence suggests that the sequences identi-
fied here may stimulate influenza-specific T helper cells that can 
limit disease through activation of cellular and humoral immune 
mechanisms reported to be critical for immunity. Not only do 
CD4+ T cells play a role in the rate of viral clearance,25 but memory 
helper T cells specific to a previous influenza strain contribute to 
distinct cross-strain antibody responses.28 Thus, influenza vaccine 
strategies that focus the T cell response on cross-reactive sequences 
may harness cellular and humoral mechanisms with the potential 
to provide group-common protection against disease.
Materials and Methods
Immunoinformatics. Sequence collection. Hemagglutinin and 
neuraminidase sequences were obtained from the NIAID 
Influenza Research Database (http://www.fludb.org).39 H1N1 
HA and NA sequences isolated from human hosts and depos-
ited between January 1980 and June 2011 were downloaded and 
annotated by origin. Swine origin viral isolates were designated 
Table 2. cultured human IFNγ eLISpot responses to influenza H1N1 IcS peptides
844 (DR1, DR4) 1489 (DR1, DR4) 1003 (DR4, DR4) 720 (DR1, DR7) 1442 (DR4, DR13) % 
Subjects 
PositiveSFC SI p-value SFC SI p-value SFC SI p-value SFC SI p-value SFC SI p-value
Ha-1 143 1.30 0.346 267 1.23 0.129 397 5.17  < 0.001 293 11.00 0.001 507 0.85 0.217 40%
Ha-2 137 1.24 0.506 207 0.95 0.741 177 2.30 0.002 310 11.63  < 0.001 540 0.91 0.327 40%
Ha-3 117 1.06 0.863 603 2.78  < 0.001 1180 15.39  < 0.001 280 10.50  < 0.001 2297 3.87  < 0.001 80%
Ha-4 137 1.24 0.529 610 2.82 0.005 1000 13.04  < 0.001 587 22.00  < 0.001 1023 1.72 < 0.001 60%
Ha-5 97 0.88 0.711 170 0.78 0.171 70 0.91 0.733 103 3.88  < 0.001 480 0.81 0.042 20%
Ha-6 120 1.09 0.797 120 0.55 0.035 30 0.39 0.036 13 0.50 0.121 687 1.16 0.116 0%
Ha-7 150 1.36 0.301 163 0.75  0.143 107 1.39 0.142 57 2.13 0.184 760 1.28 0.029 0%
Ha-8 153 1.39 0.231 810 3.74  < 0.001 1217 15.87  < 0.001 163 6.13 0.034 1277 2.15  < 0.001 80%
Ha-9 133 1.21 0.521 210 0.97 0.856 160 2.09 0.003 43 1.63 0.063 530 0.89 0.365 20%
Ha-10 190 1.73 0.081 263 1.22 0.301 147 1.91 0.008 53 2.00 0.032 513 0.87 0.185 20%
Ha-11 203 1.85 0.080 820 3.78  < 0.001 837 10.91  < 0.001 177 6.63 0.001 777 1.31 0.034 60%
Ha-13 110 1.00 1.000 190 0.88 0.529 97 1.26 0.316 50 1.88 0.036 497 0.84 0.071 0%
Ha-19 83 0.76 0.477 170 0.78 0.154 3763 49.09  < 0.001 73 2.75 0.028 3643 6.14  < 0.001 60%
Na-1 140 1.27 0.390 200 0.92 0.580 127 1.65 0.147 143 5.38 0.009 630 1.06 0.470 20%
Na-2 143 1.30 0.346 230 1.06 0.740 270 3.52  < 0.001 117 4.38  < 0.001 517 0.87 0.226 40%
Na-3 147 1.33 0.318 260 1.20 0.279 200 2.61 0.006 33 1.25 0.553 537 0.90 0.494 20%
Na-4 150 1.36 0.270 210 0.97 0.873 103 1.35 0.385 27 1.00 1.000 580 0.98 0.795 0%
IcS 
pool 223 2.03 0.026 2457 11.34  < 0.001 4813 62.78  < 0.001 1153 43.25  < 0.001 3971 6.69  < 0.001 100%
Immunoreactivity data for influenza H1N1 IcS peptides are presented from cultured IFNγ eLISpot assays performed for five human subjects. an eLISpot 
response was considered positive if three criteria were met: (1) spot-forming cells (SFc) per million pBMc were at least 50, (2) SFc per million pBMc 
were at least 2-fold over background, and (3) SFc per million pBMc were statistically different from “no stimulus” measurements by the Student’s t-test 
(p < 0.05). Results that meet individual criteria are highlighted in gray. Results that meet all three criteria are denoted in bold. column headers: human 
subject ID code and HLa class II type in parentheses; numbers of spot forming cells per million pBMcs that secrete IFNγ in response to individual and 
pooled IcS peptides (SFc); stimulation indices (SI); and Student’s t-test results (p-value); and percent of subjects responding. Row labels: peptide ID. 
epitopes are grouped according to their source antigen, either Ha or Na. It is possible Subject 844 did not respond strongly to the IcS peptides be-
cause of no prior history of H1N1 exposure or vaccination.
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multiple HLA alleles. A competition-based HLA binding format 
was adapted from Steere et al.45 Briefly, in racks of 1.1 ml tubes, 
non-biotinylated test peptides over a wide range of concentra-
tions competed for binding to soluble class II molecules (2.5 nM) 
against a biotinylated standard peptide at a fixed concentra-
tion (25 nM) at 37°C for 24 h to reach equilibrium. Class II 
molecules were then captured on ELISA plates using pan anti-
Class II antibodies (L243, anti-HLA-DR). Plates were washed 
and incubated with Europium-labeled streptavidin for one hour 
at room temperature. Europium activation buffer was added to 
develop the plates for 15–20 min at room temperature before 
they were read on a Time Resolved Fluorescence (TRF) plate 
reader. All assays were performed in triplicate. Dose dependence 
curves were generated by fitting data using the four-parameter 
logistic equation, and IC
50
 values were calculated in SigmaPlot 
11.0 (Systat, Chicago, IL). Based on the IC
50
 values, peptide 
binding to a given HLA allele was classified as very high affinity 
(< 100 nM), high affinity (100–1,000 nM), moderate affinity 
(1000–10,000 nM), low affinity (10,000–100,000 nM), or very 
low affinity (> 100,000 nM). Peptides that did not inhibit the 
binding of the biotinylated reference peptide at any concentration 
were considered non-binders. Binding assays were performed for 
six alleles: DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, 
DRB1*1101 and DRB1*1501, providing a broad representation of 
class II HLA allele binding pockets.41
PBMC collection and characterization. Frozen PBMCs 
donated by five healthy adults, ages 18 to 65 y, were generously 
provided by VaxDesign. No information on influenza vac-
cination or exposure was provided. Donor HLA class II types 
were determined using the One Lambda Micro SSPTM High 
Resolution HLA class II kit at the Hartford Hospital Transplant 
Immunology Laboratory. Human subject studies were performed 
in accordance with NIH regulations and with the approval of 
the Ethical and Independent Review Services institutional review 
board.
PBMC culture. Thawed whole PBMC populations were 
rested overnight and then expanded by antigen stimulation over 
nine days at 37°C under a 5% CO
2
 atmosphere. In a 48-well 
plate, 5 × 106 cells in 150 μl Iscove’s Modified Dulbecco’s 
Medium (IMDM) were stimulated with a pool of HA and NA 
ICS peptides at 10 μg/ml on Day 1. Three days later, IL-2 was 
added to 10 ng/ml and the culture volume raised to 300 μl. On 
Day 7, cells were supplemented with 10 ng/ml IL-2 by half media 
replacement. Finally, two days later, PBMCs were collected and 
washed in preparation for antigen re-stimulation to measure 
cytokine secretion measurements by enzyme-linked immunospot 
(ELISpot) assay.
ELISpot assay. Interferon-gamma (IFNγ) ELISpot assays 
were performed using kits purchased from Mabtech and per-
formed according to the manufacturer’s specifications. Target 
peptides were added individually at 10 μg/ml and pooled at 1.25 
μg/ml to triplicate wells containing 100,000 PBMCs in IMDM 
supplemented with 10% human AB serum. Cells were incubated 
for 48 h at 37°C under a 5% CO
2
 atmosphere. Triplicate wells 
were plated with PHA (10 μg/ml) as a positive control, and six 
wells with no peptide were used for background determination. 
conservation analysis and EpiMatrix analysis.7 ICS are class II 
epitope-length peptides of 20–25 residues each, whose compo-
sition has been enriched for both HLA binding potential and 
pathogen strain coverage using 9-mers from multiple isolates 
aligned by position in their native protein sequence. By definition, 
an ICS is seeded with a core 9-mer, and overlapping regions are 
subsequently screened for high-scoring, highly conserved 9-mer 
candidates to append until the optimal peptide length is reached. 
The resulting ICS peptides are compact clusters of putative T cell 
epitopes, each offering the advantage of targeting multiple strains 
and widely variable individual hosts using a single sequence. A 
conservation threshold was set such that the constituent 9-mer 
frames of each resulting ICS were required, in aggregate, to cover 
a minimum of 75% of input protein sequences.
Homology analysis. To eliminate peptide candidates unlikely 
to stimulate effector T cell responses, H1N1 ICS sequences were 
screened for homology against a set of host and commensal pro-
tein databases using the BLAST algorithm and parameters estab-
lished as standards for short (peptide-length) sequences. Given that 
viral epitopes may stimulate regulatory T cell responses, ICS were 
screened against the complete human genome and the complete 
murine genome. Sequences were also screened against human 
commensals cataloged as part of the Human Microbiome Project 
(www.hmpdacc.org/resources/data_browser.php),42 as well as 
the larger GenBank non-redundant protein database—excluding 
influenza—to identify homologous sequences in other pathogens. 
Standards have been established for the annotation and finishing 
of microbial genome sequences.43,44 All genomes at Finishing Level 
3 (High Quality Draft) and above as of April 2011 were used to 
construct a local database of human microbiome sequences against 
which to screen H1N1 peptides. Finally, to establish whether any 
H1N1 ICS might stimulate cross-reactive T cell responses in other 
potential pandemic influenza outbreaks, peptides were screened 
against all H5N1 sequences isolated from humans and available 
at the GISAID database for influenza sequence sharing (http://
platform.gisaid.org) as of June 2011. As a general practice, any ICS 
sharing more than seven amino acid identities per 9-mer frame was 
tagged; results of homology analysis against these five databases 
were reviewed on a case-by-case basis.
ICS selection. ICS peptides were manually reviewed to elimi-
nate redundancy of core sequences due to similar, though not 
identical, motifs across isolates. Ambiguity due to sequences con-
taining unidentifiable residues at certain positions was corrected. 
ICS with significant homology to host genomes were excluded, 
whereas sequence similarity to other organisms would not neces-
sarily remove a peptide from the list of candidates. In one case, a 
highly hydrophobic ICS was hand modified by adding charged 
residues to the N-terminal flank of the peptide to increase the 
probability of successful peptide synthesis.
Peptide synthesis. Synthetic peptides were manufactured 
using 9-fluoronylmethoxycarbonyl (Fmoc) chemistry by 21st 
Century Biochemicals (Marlboro, MA). Peptide purity was > 
80% as ascertained by analytical reversed phase HPLC. Peptide 
mass was confirmed by tandem mass spectrometry.
HLA binding assay. Class II HLA binding assays were per-
formed to screen predicted epitope sequences for binding to 
D
ow
nl
oa
de
d 
by
 [7
2.2
15
.23
6.2
54
] a
t 1
2:0
7 0
8 O
cto
be
r 2
01
5 
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
1606 Human Vaccines & Immunotherapeutics Volume 9 Issue 7
privately owned biotechnology company located in Providence, 
RI. L.M. is employed by and holds stock options in EpiVax. 
These authors acknowledge that there is a potential conflict 
of interest related to their relationship with EpiVax and attest 
that the work contained in this research report is free of any 
bias that might be associated with the commercial goals of 
the company.
Acknowledgments
We are grateful to Dr Donald Drake (VaxDesign) for provid-
ing PBMC samples and to Lauren Levitz for a thorough read-
ing of the manuscript. This work was supported by NIH grant 
R21AI090359 (ADG).
Raw spot counts were recorded by ZellNet Consulting, Inc. 
using a Zeiss high-resolution automated ELISpot reader system 
and companion KS ELISpot software. Results were calculated as 
the average number of spots in the peptide wells, adjusted to spots 
per one million cells. A response was considered peptide-specific 
if the number of spots was at least twice background, greater than 
50 spot forming cells per well (1 response per 20,000 PBMCs), 
and statistically different (p < 0.05) from that of the control wells 
by the Student’s t-test.
Disclosure of Potential Conflicts of Interest
Two of the contributing authors, A.S.DG. and W.D.M., are 
senior officers and majority shareholders at EpiVax, Inc., a 
References
1. Centers for Disease Control and Prevention. 2012-
2013 Influenza Season Week 25 ending June 8, 2013. 
Centers for Disease Control and Prevention. Retrieved 
from: http://www.cdc.gov/flu/weekly/.
2. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 
Efficacy and effectiveness of influenza vaccines: a sys-
tematic review and meta-analysis. [Erratum in: Lancet 
Infect Dis 2012; 12:655; PMID:22032844; http://
dx.doi.org/10.1016/S1473-3099] [11] [70295-X]. 
Lancet Infect Dis 2012; 12:36-44; PMID:22032844; 
http://dx.doi.org/10.1016/S1473-3099(11)70295-X
3. Centers for Disease Control and Prevention (CDC). 
Serum cross-reactive antibody response to a novel influ-
enza A (H1N1) virus after vaccination with seasonal 
influenza vaccine. MMWR Morb Mortal Wkly Rep 
2009; 58:521-4; PMID:19478718
4. De Groot AS, Ardito M, McClaine EM, Moise L, 
Martin WD. Immunoinformatic comparison of T-cell 
epitopes contained in novel swine-origin influenza A 
(H1N1) virus with epitopes in 2008-2009 conven-
tional influenza vaccine. Vaccine 2009; 27:5740-7; 
PMID:19660593; http://dx.doi.org/10.1016/j.vac-
cine.2009.07.040
5. Schanen BC, De Groot AS, Moise L, Ardito M, 
McClaine E, Martin W, et al. Coupling sensitive in vitro 
and in silico techniques to assess cross-reactive CD4(+) 
T cells against the swine-origin H1N1 influenza virus. 
Vaccine 2011; 29:3299-309; PMID:21349362; http://
dx.doi.org/10.1016/j.vaccine.2011.02.019
6. Koita OA, Dabitao D, Mahamadou I, Tall M, Dao 
S, Tounkara A, et al. Confirmation of immunogenic 
consensus sequence HIV-1 T-cell epitopes in Bamako, 
Mali and Providence, Rhode Island. Hum Vaccin 2006; 
2:119-28; PMID:17012903
7. De Groot AS, Bishop EA, Khan B, Lally M, Marcon L, 
Franco J, et al. Engineering immunogenic consensus T 
helper epitopes for a cross-clade HIV vaccine. Methods 
2004; 34:476-87; PMID:15542374; http://dx.doi.
org/10.1016/j.ymeth.2004.06.003
8. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof 
I, Salimi N, et al. The immune epitope database 2.0. 
Nucleic Acids Res 2010; 38(Database issue):D854-62; 
PMID:19906713; http://dx.doi.org/10.1093/nar/
gkp1004
9. Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, 
Leng Q, Abdel Hady KM, et al. The two-faced T cell 
epitope: Examining the host-microbe interface with 
JanusMatrix. Hum Vaccin Immunother 2013; 9: In 
press; PMID:23584251; http://dx.doi.org/10.4161/
hv.24615.
10. De Groot AS, Ardito M, Moise L, Gustafson EA, Spero 
D, Tejada G, et al. Immunogenic consensus sequence 
T helper epitopes for a pan-Burkholderia biodefense 
vaccine. Immunome Res 2011; 7:7; PMID:22130150
11. Moise L, McMurry JA, Pappo J, Lee DS, Moss SF, 
Martin WD, et al. Identification of genome-derived 
vaccine candidates conserved between human and 
mouse-adapted strains of H. pylori. Hum Vaccin 
2008; 4:219-23; PMID:18376134; http://dx.doi.
org/10.4161/hv.4.3.5394
12. De Groot AS, Martin W. Reducing risk, improv-
ing outcomes: bioengineering less immunogenic 
protein therapeutics. Clin Immunol 2009; 131:189-
201; PMID:19269256; http://dx.doi.org/10.1016/j.
clim.2009.01.009
13. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, 
Sun H, et al. Cross-reactive antibody responses to the 
2009 pandemic H1N1 influenza virus. N Engl J Med 
2009; 361:1945-52; PMID:19745214; http://dx.doi.
org/10.1056/NEJMoa0906453
14. Jain S, Kamimoto L, Bramley AM, Schmitz AM, 
Benoit SR, Louie J, et al.; 2009 Pandemic Influenza 
A (H1N1) Virus Hospitalizations Investigation Team. 
Hospitalized patients with 2009 H1N1 influenza in 
the United States, April-June 2009. N Engl J Med 
2009; 361:1935-44; PMID:19815859; http://dx.doi.
org/10.1056/NEJMoa0906695
15. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, 
Vaughan K, Salimi N, et al. Pre-existing immunity 
against swine-origin H1N1 influenza viruses in the 
general human population. Proc Natl Acad Sci U S A 
2009; 106:20365-70; PMID:19918065; http://dx.doi.
org/10.1073/pnas.0911580106
16. Richards KA, Topham D, Chaves FA, Sant AJ. Cutting 
edge: CD4 T cells generated from encounter with 
seasonal influenza viruses and vaccines have broad 
protein specificity and can directly recognize natu-
rally generated epitopes derived from the live pan-
demic H1N1 virus. J Immunol 2010; 185:4998-5002; 
PMID:20889549; http://dx.doi.org/10.4049/jimmu-
nol.1001395
17. Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Qin G, et 
al. Cytotoxic T lymphocytes established by seasonal 
human influenza cross-react against 2009 pandem-
ic H1N1 influenza virus. J Virol 2010; 84:6527-
35; PMID:20410263; http://dx.doi.org/10.1128/
JVI.00519-10
18. Boon AC, de Mutsert G, van Baarle D, Smith DJ, 
Lapedes AS, Fouchier RA, et al. Recognition of homo- 
and heterosubtypic variants of influenza A viruses 
by human CD8+ T lymphocytes. J Immunol 2004; 
172:2453-60; PMID:14764717
19. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken 
T, Fouchier RA, Osterhaus AD, et al. Primary influ-
enza A virus infection induces cross-protective immu-
nity against a lethal infection with a heterosubtyp-
ic virus strain in mice. Vaccine 2007; 25:612-20; 
PMID:17005299; http://dx.doi.org/10.1016/j.vac-
cine.2006.08.036
20. Ge X, Tan V, Bollyky PL, Standifer NE, James EA, 
Kwok WW. Assessment of seasonal influenza A virus-
specific CD4 T-cell responses to 2009 pandemic H1N1 
swine-origin influenza A virus. J Virol 2010; 84:3312-
9; PMID:20071564; http://dx.doi.org/10.1128/
JVI.02226-09
21. Ellebedy AH, Ducatez MF, Duan S, Stigger-Rosser E, 
Rubrum AM, Govorkova EA, et al. Impact of prior 
seasonal influenza vaccination and infection on pan-
demic A (H1N1) influenza virus replication in ferrets. 
Vaccine 2011; 29:3335-9; PMID:20840835; http://
dx.doi.org/10.1016/j.vaccine.2010.08.067
22. Garcia-Garcia L, Valdespino-Gómez JL, Lazcano-
Ponce E, Jimenez-Corona A, Higuera-Iglesias A, Cruz-
Hervert P, et al. Partial protection of seasonal trivalent 
inactivated vaccine against novel pandemic influenza A/
H1N1 2009: case-control study in Mexico City. BMJ 
2009; 339:b3928; PMID:19808768; http://dx.doi.
org/10.1136/bmj.b3928
23. Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ, 
Hill AV, et al. Examination of influenza specific T 
cell responses after influenza virus challenge in indi-
viduals vaccinated with MVA-NP+M1 vaccine. PLoS 
One 2013; 8:e62778; PMID:23658773; http://dx.doi.
org/10.1371/journal.pone.0062778
24. Kamperschroer C, Dibble JP, Meents DL, Schwartzberg 
PL, Swain SL. SAP is required for Th cell function 
and for immunity to influenza. J Immunol 2006; 
177:5317-27; PMID:17015717
25. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty 
PC. Compromised influenza virus-specific CD8(+)-T-
cell memory in CD4(+)-T-cell-deficient mice. J Virol 
2002; 76:12388-93; PMID:12414983; http://dx.doi.
org/10.1128/JVI.76.23.12388-12393.2002
26. Cardin RD, Brooks JW, Sarawar SR, Doherty PC. 
Progressive loss of CD8+ T cell-mediated control of a 
gamma-herpesvirus in the absence of CD4+ T cells. J 
Exp Med 1996; 184:863-71; PMID:9064346; http://
dx.doi.org/10.1084/jem.184.3.863
27. Brooks JW, Hamilton-Easton AM, Christensen JP, 
Cardin RD, Hardy CL, Doherty PC. Requirement 
for CD40 ligand, CD4(+) T cells, and B cells in an 
infectious mononucleosis-like syndrome. J Virol 1999; 
73:9650-4; PMID:10516078
28. Marshall D, Sealy R, Sangster M, Coleclough C. 
TH cells primed during influenza virus infection 
provide help for qualitatively distinct antibody respons-
es to subsequent immunization. J Immunol 1999; 
163:4673-82; PMID:10528164
29. Lee LY, Ha LA, Simmons C, de Jong MD, Chau NV, 
Schumacher R, et al. Memory T cells established by 
seasonal human influenza A infection cross-react with 
avian influenza A (H5N1) in healthy individuals. J Clin 
Invest 2008; 118:3478-90; PMID:18802496
30. Townsend AR, Skehel JJ. The influenza A virus nucleo-
protein gene controls the induction of both subtype 
specific and cross-reactive cytotoxic T cells. J Exp Med 
1984; 160:552-63; PMID:6206181; http://dx.doi.
org/10.1084/jem.160.2.552
D
ow
nl
oa
de
d 
by
 [7
2.2
15
.23
6.2
54
] a
t 1
2:0
7 0
8 O
cto
be
r 2
01
5 
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com Human Vaccines & Immunotherapeutics 1607
42. Peterson J, Garges S, Giovanni M, McInnes P, Wang 
L, Schloss JA, et al.; NIH HMP Working Group. 
The NIH Human Microbiome Project. Genome Res 
2009; 19:2317-23; PMID:19819907; http://dx.doi.
org/10.1101/gr.096651.109
43. Chain PS, Grafham DV, Fulton RS, Fitzgerald MG, 
Hostetler J, Muzny D, et al.; Genomic Standards 
Consortium Human Microbiome Project Jumpstart 
Consortium. Genomics. Genome project standards 
in a new era of sequencing. Science 2009; 326:236-
7; PMID:19815760; http://dx.doi.org/10.1126/sci-
ence.1180614
44. Nelson KE, Weinstock GM, Highlander SK, Worley 
KC, Creasy HH, Wortman JR, et al.; Human 
Microbiome Jumpstart Reference Strains Consortium. 
A catalog of reference genomes from the human micro-
biome. Science 2010; 328:994-9; PMID:20489017; 
http://dx.doi.org/10.1126/science.1183605
45. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok 
WW, Nepom GT, et al. Antibiotic-refractory Lyme 
arthritis is associated with HLA-DR molecules that 
bind a Borrelia burgdorferi peptide. J Exp Med 
2006; 203:961-71; PMID:16585267; http://dx.doi.
org/10.1084/jem.20052471
37. Elfaki ME, Khalil EA, Degroot AS, Musa AM, 
Gutiérrez Núñez A, Younis BM, et al. Immunogenicity 
and immune modulatory effects of in silico predicted 
L. donovani candidate peptide vaccines. Hum Vaccin 
Immunother 2012; 8:1769-74; PMID:22922767; 
http://dx.doi.org/10.4161/hv.21881
38. Poland GA. Vaccines against Lyme disease: What hap-
pened and what lessons can we learn? Clin Infect Dis 
2011; 52(Suppl 3):s253-8; PMID:21217172; http://
dx.doi.org/10.1093/cid/ciq116
39. Squires RB, Noronha J, Hunt V, García-Sastre A, 
Macken C, Baumgarth N, et al. Influenza research 
database: an integrated bioinformatics resource for 
influenza research and surveillance. Influenza Other 
Respi Viruses 2012; 6:404-16; PMID:22260278; 
http://dx.doi.org/10.1111/j.1750-2659.2011.00331.x
40. De Groot AS, Jesdale BM, Szu E, Schafer JR, Chicz 
RM, Deocampo G. An interactive Web site providing 
major histocompatibility ligand predictions: applica-
tion to HIV research. AIDS Res Hum Retroviruses 
1997; 13:529-31; PMID:9135870; http://dx.doi.
org/10.1089/aid.1997.13.529
41. Southwood S, Sidney J, Kondo A, del Guercio MF, 
Appella E, Hoffman S, et al. Several common HLA-DR 
types share largely overlapping peptide binding reper-
toires. J Immunol 1998; 160:3363-73; PMID:9531296
31. Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, 
Oseroff C, et al. Immunomic analysis of the repertoire 
of T-cell specificities for influenza A virus in humans. 
J Virol 2008; 82:12241-51; PMID:18842709; http://
dx.doi.org/10.1128/JVI.01563-08
32. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, 
Kleppinger A, et al. T cell responses are better correlates 
of vaccine protection in the elderly. J Immunol 2006; 
176:6333-9; PMID:16670345
33. Levitz L, Koita OA, Sangare K, Ardito MT, Boyle CM, 
Rozehnal J, et al. Conservation of HIV-1 T cell epit-
opes across time and clades: validation of immunogenic 
HLA-A2 epitopes selected for the GAIA HIV vaccine. 
Vaccine 2012; 30:7547-60; PMID:23102976; http://
dx.doi.org/10.1016/j.vaccine.2012.10.042
34. De Groot AS, Levitz L, Ardito MT, Skowron G, 
Mayer KH, Buus S, et al. Further progress on defin-
ing highly conserved immunogenic epitopes for a 
global HIV vaccine: HLA-A3-restricted GAIA vaccine 
epitopes. Hum Vaccin Immunother 2012; 8:987-
1000; PMID:22777092; http://dx.doi.org/10.4161/
hv.20528
35. De Groot AS, Rivera DS, McMurry JA, Buus S, Martin 
W. Identification of immunogenic HLA-B7 “Achilles’ 
heel” epitopes within highly conserved regions of HIV. 
Vaccine 2008; 26:3059-71; PMID:18206276; http://
dx.doi.org/10.1016/j.vaccine.2007.12.004
36. De Groot AS, Ardito M, Terry F, Levitz L, Ross TM, 
Moise L, et al. Low immunogenicity predicted for 
emerging avian-origin H7N9: Implication for influenza 
vaccine design. Hum Vaccin Immunother 2013; 9: In 
press; PMID:23807079; http://dx.doi.org/10.4161/
hv.24939.
D
ow
nl
oa
de
d 
by
 [7
2.2
15
.23
6.2
54
] a
t 1
2:0
7 0
8 O
cto
be
r 2
01
5 
